-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

631. Chronic Myeloid Leukemia: Biology and Pathophysiology, excluding Therapy: Poster III

Program: Oral and Poster Abstracts
Type: Poster
Monday, December 3, 2018: 6:00 PM-8:00 PM
Hall GH (San Diego Convention Center)

Tatjana Bilich1,2*, Annika Nelde1,2*, Leon Bichmann1,3*, Helmut R. Salih, MD4,5, Daniel Johannes Kowalewski1,6*, Heiko Schuster1,6*, Ana Marcu1*, Marian C. Neidert7*, Maren Lübke1*, Jonas Rieth1*, Mirle Schemionek8*, Tim H Brümmendorf, MD8, Vladan Vucinic9*, Dietger Niederwieser, MD10, Melanie Märklin, PhD2*, Janet K. Peper1*, Malte Roerden2*, Reinhild Klein2*, Oliver Kohlbacher3,11,12,13*, Lothar Kanz2, Hans-Georg Rammensee1,14*, Stefan Stevanovic1,14* and Juliane S. Walz2*

1Institute for Cell Biology, Department of Immunology, University of Tübingen, Tübingen, Germany
2Department of Hematology and Oncology, University Hospital Tübingen, Tübingen, Germany
3Applied Bioinformatics, Center for Bioinformatics and Department of Computer Science, University of Tübingen, Tübingen, Germany
4Clinical Cooperation Unit Translational Immunology, German Cancer Consortium (DKTK), DKFZ partner site Tübingen, Tübingen, Germany
5Department of Internal Medicine II, University Hospital Tuebingen, Tuebingen, Germany, Tuebingen, Germany
6Immatics Biotechnologies GmbH, Tübingen, Germany
7Department of Neurosurgery, Clinical Neuroscience Center, University Hospital Zurich and University of Zurich, Zurich, Switzerland
8Department of Hematology, Oncology, Hemostaseology, and Stem Cell Transplantation, University Hospital RWTH Aachen University, Aachen, Germany
9Department of Hematology and Oncology, University of Leipzig, Leipzig, Germany
10Department of Hematology and Oncology, University Hospital Leipzig, Leipzig, Germany
11Quantitative Biology Center, University of Tübingen, Tübingen, Germany
12Biomolecular Interactions, Max-Planck-Institute for Developmental Biology, Tübingen, Germany
13Institute for Translational Bioinformatics, University Hospital Tübingen, Tübingen, Germany
14German Cancer Consortium (DKTK), DKFZ Partner Site Tübingen, Tübingen, Germany

Elisabetta Abruzzese, MD1, Monica Bocchia, MD, PhD2*, Simona Bernardi, PhD3*, Malgorzata Monika Trawinska, MD4*, Donatella Raspadori, PhD5*, Camilla Zanaglio, PhD3*, Francesco Bondanini, MD6*, Anna Sicuranza, PhD5*, Paola Pacelli, PhD7*, Michele Malagola, MD8 and Paolo de Fabritiis, MD9*

1S. Eugenio Hospital, Tor Vergata University, Rome, Italy
2Chair of Hematology, University of Siena, Azienda Ospedaliera Universitaria, Siena, Italy
3Bone Marrow Transplant Unit, ASST-Spedali Civili di Brescia, Chair of Hematology, Dpt of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy
4Tor Vergata University, Hematology, S. Eugenio Hospital, Roma, ITA
5Hematology, University of Siena, Siena, Italy
6Laboratory Medicine Unit, S. Eugenio Hospital, rome, Italy
7Hematology, AOUS, University of Siena, Siena, Italy
8Bone Marrow Transplant Unit, ASST-Spedali Civili di Brescia, Spedali Civili, Brescia, Italy
9Hematology, S. Eugenio Hospital, Tor Vergata University, Roma, Italy

Jun Toda, MD1*, Michiko Ichii, MD, PhD1*, Hirohiko Shibayama, MD, PhD1, Hideaki Saito, MD1*, Yuichi Kitai2*, Ryuta Muromoto2*, Jun-ichi Kashiwakura2*, Kodai Saitoh2*, Tadashi Matsuda2*, Kenji Oritani, MD, PhD3* and Yuzuru Kanakura, MD, PhD1

1Department of Hematology and Oncology, Osaka University Graduate School of Medicine, Suita, Japan
2Department of Immunology, Graduate School of Pharmaceutical Sciences, Hokkaido University, Sapporo, Japan
3Department of Hematology, International University of Health and Welfare, Narita, JPN

Hee-Don Chae, PhD1*, Lara C. Murphy, MD1,2*, Michele Donato, PhD2,3*, Alex G. Lee, PhD4*, E. Alejandro Sweet-Cordero, MD, PhD4*, Parveen Abidi, PhD5*, Henrique Bittencourt, MD, PhD6, Norman J. Lacayo, MD1, Gary Van Houten Dahl, MD1, Catherine Aftandilian, MD7, Kara L. Davis, DO1, Min Huang, PhD1*, Nathan Sumarsono, BS1*, Michele Redell, MD, PhD8, Cecilia H. Fu, MD9, I-Ming L. Chen, DVM, MS10, Todd A Alonzo, PhD11*, Elizabeth A. Eklund, MD12, Jason R. Gotlib, MD, MS5, Purvesh Khatri, PhD2,3*, Nobuko Hijiya, MD13 and Kathleen M. Sakamoto, MD, PhD1

1Department of Pediatrics, Stanford University School of Medicine, Stanford, CA
2Institute for Immunity, Transplantation and Infection, Stanford University, Stanford, CA
3Stanford Center for Biomedical Informatics Research, Stanford University School of Medicine, Stanford, CA
4Department of Pediatrics, Benioff Children's Hospital, University of California San Francisco, San Francisco, CA
5Department of Medicine, Stanford University School of Medicine, Stanford, CA
6Hematology Oncology Division, CHU Sainte-Justine, Montreal, QC, Canada
7Department of Pediatrics, Lucile Packard Children's Hospital, Palo Alto, CA
8Division of Pediatric Hematology/Oncology, Baylor College of Medicine, Houston, TX
9Division of Hematology/Oncology, Children's Hospital Los Angeles, Los Angeles, CA
10Department of Pathology, University of New Mexico Cancer Rsch Facility, Albuquerque, NM
11Children’s Oncology Group, Department of Preventive Medicine, University of Southern California, Monrovia, CA
12Division of Hematology/Oncology, Northwestern University Feinberg School of Medicine, Chicago, IL
13Department of Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, IL

Xiuyan Zhang1*, Yu Wang1*, Lun Xiao1*, Haixia Zhou, MD, PhD2*, Li Zhu, MD, PhD1 and Yun Zhao, PhD1*

1Cyrus Tang Hematology Center, Soochow University, Suzhou, China
2The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, Suzhou, China

Anna Reister Schultz, BS1*, Thomas Jacob2,3,4*, Christopher A. Eide5,6*, Samantha L Savage1*, Motomi Mori, PhD7*, Jeffrey W. Tyner, PhD8,9, Cristina E. Tognon, PhD1,6*, Tania Q. Vu2,3,10* and Brian J. Druker, MD6,11

1Knight Cancer Institute, Division of Hematology and Medical Oncology, Oregon Health & Science University, Portland, OR
2Department of Biomedical Engineering, Oregon Health & Science University, Portland, OR
3OHSU Center for Spatial Systems Biomedicine, Oregon Health & Science University, Portland, OR
4Knight Cancer Institute, Oregon Health & Science University, Portland
5Knight Cancer Institute, Division of Hematology & Medical Oncology, Oregon Health & Science University, Portland, OR
6Howard Hughes Medical Institute, Portland, OR
7Knight Cancer Institute, Biostatistics Shared Resource, Oregon Health & Science University, Portland, OR
8Department of Cell, Developmental & Cancer Biology, Oregon Health & Science University, Knight Cancer Institute, Portland, OR
9Knight Cancer Institute, Department of Cell, Developmental and Cancer Biology, Oregon Health and Science University, Portland, OR
10Knight Cancer Institute, Oregon Health & Science University, Portland, OR
11Knight Cancer Institute, Oregon Health and Science University, Portland, OR

Seiichi Okabe, MD, PhD1*, Tetsuzo Tauchi, MD, PhD1*, Yuko Tanaka2* and Kazuma Ohyashiki, MD, PhD1

1Department of Hematology, Tokyo Medical University, Tokyo, Japan
2Department of Hematology, Tokyo Medical University, Shinjuku-Ku, TKY, Japan

*signifies non-member of ASH